Tanja Aarvak

Dr. Tanja Aarvak is Director of Portfolio and Program Management at ARTBIO, where she is responsible for leading and overseeing development programs in Pb-212 targeted radiopharmaceuticals. She brings more than a decade of experience in radioligand therapy, spanning preclinical translation, early-phase clinical development, and registration-oriented activities. Her expertise includes program strategy, cross-functional portfolio execution across scientific, clinical, CMC, regulatory, and operational functions as well as the advancement of targeted alpha therapy platforms. Dr. Aarvak combines scientific insight with operational leadership to support the translation of innovative radiopharmaceutical approaches into clinically meaningful therapeutic opportunities for patients.